Potential therapy removes APOE and plaques from brain
Years before people start showing characteristic symptoms of Alzheimer’s disease, sticky plaques begin forming in their brains, damaging nearby cells. For decades, doctors have sought ways to clear out these plaques as a way to prevent or treat the disease.
The sticky clumps, known as amyloid plaques, are composed primarily of a brain protein called amyloid beta. But nestled within the plaques are small amounts of another Alzheimer’s protein: APOE. Now, researchers at Washington University School of Medicine have shown that an antibody not only targets APOE for removal but sweeps away plaques.
The findings, available March 26 in the Journal of Clinical Investigation, could lead to a way to halt the brain damage triggered by amyloid plaques while the disease is still in its early stages, perhaps before symptoms appear.
“Many people build up amyloid over many years, and the brain just can’t get rid of it,” said senior author David Holtzman, MD, the Andrew B. and Gretchen P. Jones Professor and head of the Department of Neurology. “By removing plaques, if we start early enough, we may be able to stop the changes to the brain that result in forgetfulness, confusion and cognitive decline.”
Variants of the gene APOE are the single largest risk factor for Alzheimer’s disease. In earlier work, Holtzman and colleagues have shown that a DNA-based compound that targets APOE can lessen the injury caused by amyloid plaques.
But getting rid of the plaques likely would protect the brain better than blunting the plaques’ destructiveness. To find out whether the plaques could be removed, Holtzman, co-first authors Fan Liao, PhD, a postdoctoral researcher, and Aimin Li, PhD, a senior scientist, and colleagues focused on antibodies that recognize and bind to APOE. Once antibodies attach themselves to their APOE target, they attract the attention of roving immune cells, which carry both antibody and target off to be destroyed. The researchers reasoned that nearby amyloid might be cleared away along with APOE.
The researchers tested several antibodies that recognize human APOE in mice genetically predisposed to develop amyloid plaques. The APOE genes of the mice had been replaced with a human APOE gene. The antibodies were developed in collaboration with Denali Therapeutics.
For six weeks, the mice were given weekly injections of placebo or antibodies against APOE. Then, the researchers measured the amount of plaques in their brains. One antibody – called HAE-4 – cut the level of plaques by half.
Moreover, HAE-4 had no effect on APOE levels in the blood. APOE plays an important role in transporting fats and cholesterol in the body, so removing it from the bloodstream could create unwanted side effects. The failure of the antibody to lower levels of APOE in the blood was therefore a good sign. But it was also a mystery. Why did the antibody clear APOE from the brain but not the blood?
“It turns out that the APOE in the plaques has a different structure than the form of APOE found in the blood,” Holtzman said. “The HAE-4 antibody recognized only the form found attached to the plaques in the brain.”
No treatment exists to prevent or delay onset – or slow the trajectory – of Alzheimer’s disease. But a few antibodies that clear plaques by targeting amyloid beta are being evaluated in clinical trials. While such antibodies are promising, they sometimes come with the side effect of inflammation and swelling in the brain.
However, antibodies that target APOE may be successful at removing plaques in people and somewhat less likely to trigger a destructive immune response, Holtzman said.
“The anti-amyloid antibodies are going to be binding to most of the molecules that are in the plaque, but the anti-APOE antibody would target just a very small component of the plaque,” Holtzman said. “This means we may find less immune activation, and we might not see the unwelcome side effects.”
The researchers are planning further studies to determine whether similar antibodies are safe and might be effective enough to be used in people.
The Latest on: Alzheimer’s plaques
via Google News
The Latest on: Alzheimer’s plaques
- Failure of once-promising Alzheimer’s drug reinforces doubts about amyloid beta on April 18, 2019 at 11:12 am
It had made its way into two Phase III trials thanks to Phase Ib data demonstrating its efficacy at reducing plaques of the peptide amyloid beta — a defining feature of Alzheimer’s disease ... […]
- UCSB Researchers Find Novel Genetic Mutation for Alzheimer’s Disease on April 18, 2019 at 9:08 am
When you have mutations in this gene, this complex doesn’t work properly, and favors the cleavage of amyloid precursor protein into amyloid beta, which forms aggregates that are called plaques and is ... […]
- To fight Alzheimer’s disease, Univ. of Washington researchers target plaque-causing proteins | GeekWire on April 17, 2019 at 10:45 pm
Editor's note: the video above was first created in March 2019. Researchers at the University of Washington have created a molecule that aims to stop the formation of protein clusters thought to be a ... […]
- Targeting senescence within the Alzheimer’s plaque on April 17, 2019 at 11:42 am
Amyloid β drives senescence of oligodendrocyte progenitor cells, presenting a potential therapeutic target. The term “cellular senescence” describes a condition in which cells undergo irreversible ... […]
- Alzheimer's: Synthetic protein blocks toxic beta-amyloid on April 16, 2019 at 7:51 pm
In Alzheimer's disease, the oligomers continue to grow into longer shapes, and then eventually, they form much bigger deposits, or plaques. At first, scientists thought that plaques were the most ... […]
- To fight Alzheimer’s disease, Univ. of Washington researchers target plaque-causing proteins on April 16, 2019 at 4:31 pm
Researchers developed a synthetic peptide to stop the formation of protein clusters that are thought to cause cognitive problems in patients with Alzheimer’s disease. (University of Washington Photo) ... […]
- Alzheimer’s Disease Toxicity Halted by Synthetic Peptides on April 16, 2019 at 7:00 am
Alzheimer’s disease (AD) is characterized by the formation of large, insoluble deposits, or plaques, of amyloid-β peptide (Aβ) in the brain. These plaques are generated by the aggregation of smaller, ... […]
- Is Alzheimer's Hereditary? on April 15, 2019 at 12:40 pm
Two abnormal structures called plaques and tangles are prime suspects in damaging and killing nerve cells in the brain that lead to Alzheimer's disease, Fargo says. Plaques are deposits of a ... […]
- Synthetic peptide can inhibit toxicity, aggregation of protein in Alzheimer's disease on April 15, 2019 at 12:05 pm
For years, scientists believed that the plaques triggered the cognitive impairments characteristic of Alzheimer's disease. But newer research implicates the smaller aggregates of amyloid beta as ... […]
via Bing News